Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 55
Recruiting: 38
Ph III recruiting: 5
Growth YoY: —
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (10)

clinicaltrialsPublishedShowing 1–16 of 16 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03581942	Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)	completed	Phase 1 / Phase 2	18	Memorial Sloan Kettering Cancer CenterOTHER	1	Feb 9, 2026	clinicaltrials
NCT02315326	Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)	completed	Phase 1 / Phase 2	93	Memorial Sloan Kettering Cancer CenterOTHER